PMID

Data

Article Title

Organization

Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet?-cells from apoptosis.

East China Normal University

Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers.

Sichuan University and Collaborative Innovation Center For Biotherapy

New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities.

China Pharmaceutical University

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs.

Eli Lilly

Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.

Merck Research Laboratories

Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors.

Nanjing University

Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.

Cellzome

Recent results in protein kinase inhibition for tropical diseases.

Montclair State University

Selectivity and potency of cyclin-dependent kinase inhibitors.

Georgetown University

Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.

Abbott Laboratories

Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.

Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories

1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.

RhôNe-Poulenc Rorer

Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.

Aristotle University of Thessaloniki

From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.

University of Illinois At Chicago

A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets.

Griffith University

Palbociclib and Michael-acceptor hybrid compounds as CDK4/6 covalent inhibitors: Improved potency, broad anticancer spectrum and overcoming drug resistance.

Southeast University

Discovery of Novel

Shenyang Pharmaceutical University

A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.

Mizoram University

Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions.

Sichuan University

CDK9 inhibitors in cancer research.

Nankai University

Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.

Menoufia University

Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9.

Banyu Tsukuba Research Institute

FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.

China Pharmaceutical University

FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.

Zhengzhou University

Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.

Hefei University of Technology

Kinase Inhibitors as Underexplored Antiviral Agents.

Centro De Investigaciones Biol�Gicas Margarita Salas (Csic)

Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.

Csir-Indian Institute of Integrative Medicine

Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.

Central South University

Design and Synthesis of a 2-Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy.

Anhui Medical University

Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT.

Zhejiang University

Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia.

China Pharmaceutical University

Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.

Chinese Academy of Sciences

Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.

China Pharmaceutical University

Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.

China Pharmaceutical University

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.

Astrazeneca

Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.

The First Affiliated Hospital of Zhengzhou University

Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13.

Harvard Medical School

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?

Lebanese American University

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).

Eli Lilly

Recent advances in the development of cyclin-dependent kinase 7 inhibitors.

Tianjin University of Science and Technology

Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents.

Chengdu University

A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.

China Pharmaceutical University

Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.

University of Padova

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.

University of South Australia Cancer Research Institute

Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.

Central University of Punjab

Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.

Jiangnan University

Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.

Beijing University of Technology

Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors.

Shanghai Haihe Pharmaceutial

Discovery of the selective and efficacious inhibitors of FLT3 mutations.

China Pharmaceutical University

Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.

University of Chinese Academy of Sciences